539 related articles for article (PubMed ID: 25355310)
1. A randomized, double-blind, placebo-controlled study of breath powered nasal delivery of sumatriptan powder (AVP-825) in the treatment of acute migraine (The TARGET Study).
Cady RK; McAllister PJ; Spierings EL; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2015 Jan; 55(1):88-100. PubMed ID: 25355310
[TBL] [Abstract][Full Text] [Related]
2. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
3. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered
Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J
Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569
[TBL] [Abstract][Full Text] [Related]
4. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Mean Level and Within-Person Consistency in Migraine Pain Intensity and Migraine-Related Disability for AVP-825 vs Oral Sumatriptan: Results from the COMPASS Study, A Randomized Trial.
McGinley JS; Buse DC; Shulman KJ; Wirth RJ; Hugentobler E; Lipton RB
Headache; 2019 Jul; 59(7):1002-1013. PubMed ID: 31062349
[TBL] [Abstract][Full Text] [Related]
6. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
[TBL] [Abstract][Full Text] [Related]
7. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.
Winner P; Rothner AD; Wooten JD; Webster C; Ames M
Headache; 2006 Feb; 46(2):212-22. PubMed ID: 16492230
[TBL] [Abstract][Full Text] [Related]
8. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea.
Schulman EA
Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837
[TBL] [Abstract][Full Text] [Related]
9. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets.
Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS
Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814
[TBL] [Abstract][Full Text] [Related]
10. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
Silberstein SD
Expert Opin Drug Saf; 2018 Jan; 17(1):89-97. PubMed ID: 28994319
[TBL] [Abstract][Full Text] [Related]
11. A novel intranasal breath-powered delivery system for sumatriptan: a review of technology and clinical application of the investigational product AVP-825 in the treatment of migraine.
Cady R
Expert Opin Drug Deliv; 2015; 12(9):1565-77. PubMed ID: 26119828
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial of Ketorolac vs. Sumatripan vs. Placebo Nasal Spray (KSPN) for Acute Migraine.
Rao AS; Gelaye B; Kurth T; Dash PD; Nitchie H; Peterlin BL
Headache; 2016 Feb; 56(2):331-40. PubMed ID: 26840902
[TBL] [Abstract][Full Text] [Related]
13. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study.
Derosier F; Sheftell F; Silberstein S; Cady R; Ruoff G; Krishen A; Peykamian M
Headache; 2012 Apr; 52(4):530-43. PubMed ID: 22103635
[TBL] [Abstract][Full Text] [Related]
14. Improved pharmacokinetics of sumatriptan with Breath Powered™ nasal delivery of sumatriptan powder.
Obaidi M; Offman E; Messina J; Carothers J; Djupesland PG; Mahmoud RA
Headache; 2013 Sep; 53(8):1323-33. PubMed ID: 23992438
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD009663. PubMed ID: 22336867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sumatriptan tablets in migraineurs self-described or physician-diagnosed as having sinus headache: a randomized, double-blind, placebo-controlled study.
Ishkanian G; Blumenthal H; Webster CJ; Richardson MS; Ames M
Clin Ther; 2007 Jan; 29(1):99-109. PubMed ID: 17379050
[TBL] [Abstract][Full Text] [Related]
17. Sumatriptan (oral route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008615. PubMed ID: 22336849
[TBL] [Abstract][Full Text] [Related]
18. Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine.
Diamond S; Elkind A; Jackson RT; Ryan R; DeBussey S; Asgharnejad M
Arch Fam Med; 1998; 7(3):234-40. PubMed ID: 9596457
[TBL] [Abstract][Full Text] [Related]
19. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD009665. PubMed ID: 22336869
[TBL] [Abstract][Full Text] [Related]
20. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study.
Djupesland PG; Docekal P;
Cephalalgia; 2010 Aug; 30(8):933-42. PubMed ID: 20656704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
